Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting 194 enrolled Merus B.V.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.

Timeline

Start: 2021-04-28
Primary completion: 2026-03
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Osimertinib	Small molecule	80 mg	Oral
Subject	PAMVATAMIG	Monoclonal antibody	—	Intravenous

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Summary

Timeline

Drugs

Indications